Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Trump Says Anthropic No Longer Seen as National Security Threat 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
JERSEY CITY, N.J., Feb. 03, 2016 -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor conferences in February:
- Leerink Partners 5th Annual Global Healthcare Conference at the Waldorf Astoria Hotel in New York City on Thursday, February 11, 2016 at 8:55 a.m. ET; and
- RBC Capital Markets 2016 Healthcare Conference at the New York Palace Hotel in New York City on Wednesday, February 24, 2016 at 11:30 a.m. ET.
A live webcast of each presentation will be available on the investors section of the Company's website: www.scynexis.com. A replay of each presentation will be available approximately two hours after each event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS, Inc. is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.
CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781.235.3060 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
